Annual meet on Epidemiology and Public Health October 21-22, 2019 Amsterdam, Netherlands

Track 1:  Genetic Epidemiology

Genetic Epidemiology is a mixture of several methods such as traditional epidemiology, population and family-based epidemiology, statistics, and also from bioinformatics. It is the study of the aetiology, distribution, and control of disease in groups of relatives and of inherited causes of disease in populations. From the parent disciplines of genetics and epidemiology, this has inherited the key elements of studying well defined populations while checking the genes roles and the environment in relation to one another and determining for the known biology of diseases. Quantifying the risk associated with genetic variation is a prerequisite for assessing the use of this new knowledge in medicine. Genetic epidemiology has the potential to impact human health.

Track 2 : Epidemiology and Medicine

Epidemiological research has been carried out traditionally in the field of non-clinical populations to reveal the etiology of disease. It is a branch of #medicine that dealing with the incidence, distribution, and control of disease in a population. In modern clinical practice, doctors used to treat patients personally and prevent disease using clinical epidemiology. The diagnosis and treatment take’s very few minutes or a few weeks depending upon the complication of the issue. Epidemiologic studies can be broadly classified into Observational studies & Experimental studies. Observational studies are also called as epidemiological studies or analytical studies. Analytical epidemiological studies are used to study the relationship between development of disease and health outcome.

Track 3 : Cancer Epidemiology

Cancer epidemiology is the study of the distribution, determination, and frequency of malignant disease in specific populations. #Cancer is the second leading cause of death globally, and is responsible for an estimation of 9.6 million deaths in 2018. Globally, about 10 in 6 deaths is due to cancer. Approximately 70% of cancer deaths are occurred in low- and middle-income countries and also some infections, such as hepatitis and human papilloma virus (HPV), are responsible for up to 25% of cancer cases. Around one third cancer deaths are occurred due to the 5 leading behavioral and dietary risks: high body mass index, low #nutrition intake, lack of physical activity, tobacco use, and alcohol consumption. Epidemiologic assessment provides the participant with a quantification of cancer risk, outlines the basis for screening modalities for high-risk populations, and determines the efficacy of any preventive intervention.

Track 4 : Sexual transmitted Infections (STI)

More than 1 million sexually transmitted infections (STIs) are seen every day worldwidly. STIs are spread predominantly by sexual contact, including vaginal, anal and oral sex. Some STIs can also be spread through non-sexual means via blood or blood products. Each year, there are an estimated 357 million new infections with 1 of 4 STIs: chlamydia, gonorrhea, syphilis and trichomoniasis other are viral infections are incurable hepatitis B, herpes simplex virus (HSV or herpes), #HIV, and human papillomavirus (HPV) can also be transmitted from mother to child during pregnancy and childbirth. Symptoms or disease can be reduced or modified through treatment. More than 500 million people are estimated to have with herpes simplex virus (HSV)and 290 million women have a human papillomavirus (HPV) infection. Common symptoms of STIs include vaginal discharge, urethral discharge or burning in men, genital ulcers, and abdominal pain.

Track 5: Immuno pharmacology

Immunopharmacology is a branch of pharmacology which concerned with the effects of drugs on the immune system. Immunopharmacology involves the study of the regulation of the immune system by pharmacological agents and the development of methods to selectively modify immune function to treat human disease. In the last 15 years, the demonstration of cellular immune defects in cancer, #aging, autoimmunity, and infectious diseases has generated interest in the development of immunotherapeutic agents. For more than 50 years, drugs targeting immune cell pathways and receptors have been extensively exploited in the treatment of inflammatory, allergic and autoimmune disorders, and in preventing rejection following organ transplantation. Among them, many non-steroidal anti-inflammatory drugs, antihistamines, corticosteroids and immunosuppressant agents have reached blockbuster status and are even included in the list of essential medicines of the World Health Organization.

Track 6 : Rare Diseases & Drug Development

Rare diseases affect small percentage of the population in recent years.  Around 80% of rare diseases are genetic in origin. Cambridge Healthtech Institute’s symposium on #Drug Discovery for Rare Diseases will bring together leading scientists, clinicians, executives and experts who are involved in finding new drug targets and drug modalities for treating rare disorders. This unique one-day event will encourage people from diverse backgrounds to discuss potential opportunities, as well as existing challenges in this field. It’s an opportunity for scientific and technical experts to come together to exchange ideas, experiences and to set up collaborations for rare disease research.

Track 7 : Epidemiology and Oral Health

Oral diseases is the most common non communicable diseases (NCDs) that which effect people throughout their lifetime by causing pain, discomfort, disfigurement and even death.The Global Burden of Disease Study 2016 estimated that half of the world’s population is effected by oral diseases like dental caries (tooth decay) in permanent teeth being the most prevalent condition fixed.In some Asian-Pacific countries, the incidence of oral cancer (cancer of the lip and oral cavity) is within the top 3 of all cancers. Dental treatment is costly, averaging 5% of total health expenditure and 20% of out-of-pocket health expenditure in most high-income countries. The oral health care demands are beyond the capacities of the health care systems in most low-and middle-income countries (LMICs). Behavioural risk factors for oral diseases are shared with other major NCDs, such as an unhealthy diet high in free sugars, tobacco use and harmful use of alcohol, exposure to fluoride have negative effects on oral health.

Track 8 : Clinical Data Management

Clinical Data Management (CDM) is used in clinical research to manage the data of a clinical trial. The clinical trial data is gathered from the investigator site in the case report form are stored in the CDMS. To reduce the possibility of errors due to human entry, the systems enlist different means to verify the entry. The most popular method is double data entry. Once the data has been screened in typographical errors, again the data is validated to check for logical errors. Another function that the #CDM  perform is the coding of data. Currently, the coding is generally centered on two areas; adverse event terms and medication names. CDM is having multidisciplinary activities like Clinical data management activities are Data acquisition/collection, Data abstraction/extraction, Data processing/coding, Data analysis, Data transmission, Data storage, Data privacy, Data QA.

Track 9 : Reproductive, Perinatal and Pediatric Epidemiology

Reproductive Epidemiology deals with the distribution and determination of diseases in human population. The main topics that which include are planning, adolescent sexual behavior, maternal morbidity and mortality ,family domestic violence, contraceptive safety and efficacy and population-based reproductive health surveys. perinatal epidemiology consists of  pregnancy side-effects such as gestational #diabetes, preeclampsia, preterm birth, birth defects, and also pregnancy outcomes. Pediatric epidemiology focus on disorders and diseases in childhood, adolescence, and young adulthood, including eating disorders, obesity, asthma, allergies, migraine, and depression.

Track 10 : Nanotechnology in drug delivery

Nanotechnology is science of theme and material that deal with particle size in nanometers. Nanotechnology has received a lot of attention because of its future potential. Nano technology offers the advantage of protecting drugs from degradation,reduce the number of doses required. It is a revolutionary technique that  which utilizes devices and molecules in the range of 1-100 nanometers. Particles exposed to nanotechnology exhibits superior characteristics including resistance to settling, higher saturation solubility state, protection from decomposition, enhanced drug release, increased adhesion to biological membranes, improved strength and reduced weight, enhanced absorption and improved chemical reactivity as compared to their larger scale corresponding item. There are different techniques for the preparation of nano drug delivery systems like nanoparticles, solid lipid nanoparticles, nanocrystals, nanosuspensions, nanoemulsions. The ultimate goal of #Nano technology is to develop useful formulation to  treat diseases in patients. Although, nanotechnology is performing good role in modern advancements from cell phones to medicines, yet it is necessary to consider their negative part as well that could be dangerous if not given proper attention. 

Track 11: Psychiatric epidemiology

Psychiatric epidemiology is a field which studies about the mental disorders in society, as well as conceptualization and prevalence of mental illness. It is a subfield of general epidemiology. However, the field has been expanded to the study of a wide area of environmental risk factors, such as major life events, as well as genetic exposures. Increasing #neuroscience techniques like MRI are used to explore the mechanisms behind the risk factors that may impact psychological problems and explore the neuroanatomical substrate underlying psychiatric disorders.

Track :12  Pharmacoepidemiology and Clinical Research

Pharmacology is the study of drugs that effect on humans in clinical studies. Part of the task is to research and assess the risk verses the benefit of drugs in patients. Epidemiology is the science that studies the patterns, causes, and effects of health and disease conditions in specified populations. Pharmacoepidemiology is therefore defined as a study of possitive and negative effects of drugs in large numbers of people or a population. Pharmacoepidemiology research at Department of Clinical Epidemiology is closely related with other research areas and clinical expertise. The research focuses on associations between use of medication and procedures in relation to outcomes of chronic and acute conditions. Our current projects examine the use of medications in relation to outcomes of infectious diseases, cardiovascular diseases, diabetes, osteoporosis, cancer, and pregnancy.

Track : 13 Renal Pharmacoepidemiology & Adrenergic drugs

Chronic kidney disease (CKD) is a type of  progressive loss in kidney function over a period of months or years.  Early on there are typically no symptoms Later, leg swelling, feeling tired, vomiting, loss of appetite, or confusion may develop.Complications may include heart disease, high blood pressure, bone disease, or anemia. A great no of  patients enrolled in the end-stage renal disease (ESRD). Although the exact reasons for the growth of the ESRD is unknown, changes in the demographics of the population, differences in disease burden among racial groups, and under-recognition of earlier stages of CKD and of risk factors for CKD may partially explain this growth .However, despite the magnitude of the resources committed to the treatment of ESRD and the substantial improvements in the quality of dialysis therapy, these patients continue to experience significant mortality and morbidity and a reduced quality of life.

Track 14: Epidemiology and chronic diseases

Research in the chronic disease epidemiology cluster addresses the etiology, prevention, distribution, natural history, and treatment outcomes of chronic health disorders, including cancer (particularly breast, colon, lung, prostate, ovary and pancreas), cardiovascular disease, diabetes, gastrointestinal and pulmonary disease, and obesity. Epidemiology role is widely accepted in public health programs but  in chronic disease programs is not as widely recognized. chronic disease program managers and public health decision makers are the one possible barrier to improe epidemiological capacity in chronic disease prevention may have a limited understanding of basic chronic disease epidemiology functions.

Track 15: Public Health and Epidemiology

Epidemiology is the study of how often diseases occur in different groups of people and why and analysis of the cause, effect, and pattern of diseases. Public health is a mixture of many different sciences and skills. It is the key discipline for public health and identifies risk factors for  the disease and targets for preventive healthcare.  It is applied to cover the description of epidemic diseases and health-related disorders like obesity and high blood pressure.  The fundamental regions of professional epidemiology having different types of epidemiologic evaluation of public health records, health affairs of state and trend analyses, public health surveillance and health software impact evaluation.

Only DRG’s Epidemiology forecasted at the total, diagnosed, and drug-treated levels – providing the complete market picture

This  foundation  is for sizing market potential, profiling patient segments and informing confident forecast-based business decisions.

Total Population

The broadest actually – not extrapolated –  the geographic coverage and  also  granular population segments for oncology, rare and niche diseases, and beyond.

The global market of Duchenne Muscular Dystrophy (DMD) was estimated to be USD 1,022 million in 2018.

This Duchenne Muscular Dystrophy - Market Insights, Epidemiology and Market Forecast-2028' reports are given in-depthly by  understanding the disease, historical & forecasted epidemiology as well as the market trends of Duchenne Muscular Dystrophy in the United States, like  Germany, Spain, Italy, France and United Kingdom and Japan.

The Report also covers current treatment, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

The Epidemiologic Research Program is a combination of both  intramural and extramural programs in the epidemiology division of the Office of Surveillance and Biometrics (OSB), a component of FDA’s Center for Devices and Radiological Health (CDRH).

ERP builds on a research infrastructure that includes a variety of organizations, collaborations, and databases, and it conducts independent research on marketed medical devices in support of CDRH regulatory decisions, including studies on safety and effectiveness, utilization and public health impact.

The ERP helps fulfill important CDRH goals by:

Monitoring medical devices and radiation-emitting devices for continued safety after they are in use; and

Disseminating accurate, science-based information on device performance.

According to this research, the global market of Recurrent Pericarditis was estimated to be USD 77.04 million in 2018. The United States accounts for the largest market size of Recurrent Pericarditis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, Germany had the highest market size worth USD 9.56 million in 2018, while Spain had the lowest market size of Recurrent Pericarditis valued at USD 3.16 million in 2018.

Epidemiology and Market Forecasts to 2028 with Focus on the United States

Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Myopia in the United States.

The Report provides the current treatment practices, emerging drugs, market share of the individual  remedy, current and forecasted market size of Myopia from 2017 to 2028 in the United States. The Report also provide current  disease practice/algorithm, market drivers, barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Market Analysis of Public Health & Epidemiology

The healthcare analytics reached $7.19 billion in 2016 and it is forecasted to grow at a CAGR of 24.0% to reach nearly $16.97 billion in 2020 from nearly $8.91billion in 2017. This analysis of global market trended with the data from 2016, estimates for 2017, and projections of CAGRs through 2020. The factors that drive the market of public health and epidemiology are the introduction of federal healthcare policies, increased focus on data collection and analysis for better customer service, progress in clinical outcomes, rapid technological advances and the emergence of social media.